Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial

Authors:

Abstract
No abstract available
Funding Information
  • Kyoto University
  • Fukushima University
  • Ministry of Health, Labour and Welfare (H30/H31/R1-Nanchi-Ippan-043)
  • Japan Agency for Medical Research and Development (JP17ek0109090)